MedTrace Logo

Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum

NCT05219994 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-07-27

No results posted yet for this study

Summary

Our overall goal is to advance our understanding of the contribution of the carotid body chemoreceptors in glucose regulation and the development of type 2 diabetes.

Conditions

Interventions

OTHER

Hyperoxia Exposure

2 hours of hyperoxia exposure during OGTT

OTHER

Normoxia Exposure

2 hours of normoxia exposure during OGTT

Sponsors & Collaborators

  • University of Missouri-Columbia

    lead OTHER

Principal Investigators

  • Jacqueline Limberg, Ph.D. · University of Missouri-Columbia

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-09
Primary Completion
2023-05-10
Completion
2023-05-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05219994 on ClinicalTrials.gov